Prebona (PREBON) Q1 2025 earnings summary

Executive summary

• Q1 2025 sales declined sharply to SEK 459,021 from SEK 2,096,185 year-over-year, mainly due to delayed product launches and high customer inventory levels; recovery expected in H2 2025.

• Notable progress in HealthCare segment, with Inodorus® gaining traction in major Swedish healthcare regions and new product launches planned.

• Strategic entry into forestry sector with NutraSol and positive test results for AgSol in antibiotic resistance, supporting long-term growth.

Financial highlights

• Net sales: SEK 459,021 (down from SEK 2,096,185 year-over-year).

• Operating income: SEK -2,468,624 (vs. SEK -865,783 year-over-year).

• Net income after financial items: SEK -2,703,809 (vs. SEK -1,211,446 year-over-year).

• EPS: SEK -0.08 (vs. SEK -0.05 year-over-year).

• Cash flow from operations: SEK -2,427,521 (vs. SEK -1,535,135 year-over-year).

• Cash and cash equivalents at period end: SEK 2,510,565.

Outlook and guidance

• Sales expected to increase in coming quarters as inventory levels normalize and new product launches ramp up.

• Management believes current liquidity and anticipated sales growth will fund operations for the next 12 months; targeted strategic initiatives may require additional financing.